Let's spread the word about Immunotherapy! Click to share this page with your community.

32nd Annual Cancer Progress Conference

Jay Campbell, Managing Director of CRI Clinical Accelerator and Venture Fund, provides an overview of oncology investment methods at the “Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My” virtual panel session on May 6.

Since 1989, Cancer Progress facilitates discussions of scientific progress in oncology within the context of development, regulatory, clinical, commercial, and investment perspectives over three days of provocative, informative panel discussions. Pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and a partnering platform enable meaningful connections and meetings with innovators, developers, and investors. 

The 32nd Annual Meeting on May 4-6, 2021, provides a learning experience for participants in quality of information, coverage of issues, and value of professional contacts. 

Cancer Progress is organized by Cello Health BioConsulting.

Register at cancerprogressbycellohealth.com.

*Immunotherapy results may vary from patient to patient.

Top